Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases, and related therapeutic adjacencies in the United States, Europe, Asia, and internationally.
Outstanding track record and good value.
Share Price & News
How has Biogen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIIB has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BIIB underperformed the Austrian Biotechs industry which returned 21.3% over the past year.
Return vs Market: BIIB exceeded the Austrian Market which returned -6.4% over the past year.
Price Volatility Vs. Market
How volatile is Biogen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Biogen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BIIB (€290) is trading below our estimate of fair value (€405.16)
Significantly Below Fair Value: BIIB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BIIB is good value based on its PE Ratio (9.9x) compared to the Biotechs industry average (36.6x).
PE vs Market: BIIB is good value based on its PE Ratio (9.9x) compared to the Austrian market (13x).
Price to Earnings Growth Ratio
PEG Ratio: BIIB's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: BIIB is overvalued based on its PB Ratio (4x) compared to the XE Biotechs industry average (3.7x).
How is Biogen forecast to perform in the next 1 to 3 years based on estimates from 28 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIIB's earnings are forecast to decline over the next 3 years (-2.2% per year).
Earnings vs Market: BIIB's earnings are forecast to decline over the next 3 years (-2.2% per year).
High Growth Earnings: BIIB's earnings are forecast to decline over the next 3 years.
Revenue vs Market: BIIB's revenue is expected to decline over the next 3 years (-0.2% per year).
High Growth Revenue: BIIB's revenue is forecast to decline over the next 3 years (-0.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIIB's Return on Equity is forecast to be high in 3 years time (25.2%)
How has Biogen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIIB has high quality earnings.
Growing Profit Margin: BIIB's current net profit margins (41%) are higher than last year (32.9%).
Past Earnings Growth Analysis
Earnings Trend: BIIB's earnings have grown by 8.9% per year over the past 5 years.
Accelerating Growth: BIIB's earnings growth over the past year (32.9%) exceeds its 5-year average (8.9% per year).
Earnings vs Industry: BIIB earnings growth over the past year (32.9%) exceeded the Biotechs industry -4.7%.
Return on Equity
High ROE: BIIB's Return on Equity (44.1%) is considered outstanding.
Return on Assets
Return on Capital Employed
How is Biogen's financial position?
Financial Position Analysis
Short Term Liabilities: BIIB's short term assets ($8.4B) exceed its short term liabilities ($4.9B).
Long Term Liabilities: BIIB's short term assets ($8.4B) do not cover its long term liabilities ($9.0B).
Debt to Equity History and Analysis
Debt Level: BIIB's debt to equity ratio (44.6%) is considered high.
Reducing Debt: BIIB's debt to equity ratio has increased from 5.4% to 44.6% over the past 5 years.
Debt Coverage: BIIB's debt is well covered by operating cash flow (118.9%).
Interest Coverage: BIIB's interest payments on its debt are well covered by EBIT (107.9x coverage).
Inventory Level: BIIB has a low level of unsold assets or inventory.
Debt Coverage by Assets: BIIB's debt is covered by short term assets (assets are 1.4x debt).
What is Biogen's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BIIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BIIB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIIB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIIB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIIB's dividend in 3 years as they are not forecast to pay a notable one for the Austrian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michel Vounatsos (57yo)
Mr. Michel Vounatsos has been the Chief Executive Officer of Biogen Inc. since January 6, 2017. Mr. Vounatsos served as the Chief Commercial Officer and Executive Vice President of Biogen Inc. since April ...
CEO Compensation Analysis
Compensation vs Market: Michel's total compensation ($USD16.17M) is above average for companies of similar size in the Austrian market ($USD3.76M).
Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.
|CEO & Director||3.1yrs||US$16.17m||0.018% $9.4m|
|Executive VP & CFO||2.2yrs||US$4.48m||0.0018% $929.6k|
|Executive VP||2.9yrs||US$6.35m||0.021% $10.9m|
|VP & Chief Accounting Officer||1.3yrs||no data||0.00014% $72.7k|
|Senior VP & Chief Information Officer||2.2yrs||no data||no data|
|VP of Finance and Head of Investor Relations||0yrs||no data||no data|
|Executive Vice President of Corporate Development||1.7yrs||no data||0.00053% $275.2k|
|Executive VP & Chief Human Resources Officer||2.6yrs||no data||0.0026% $1.4m|
|Executive Vice President of Pharmaceutical Operations & Technology||0.3yrs||no data||0.0020% $1.0m|
|Executive VP of Research & Development||8yrs||US$8.17m||0.0083% $4.3m|
Experienced Management: BIIB's management team is considered experienced (2.2 years average tenure).
|CEO & Director||3.1yrs||US$16.17m||0.018% $9.4m|
|Independent Director||10.1yrs||US$412.45k||0.011% $5.7m|
|Independent Chairman of the Board||5.7yrs||US$613.48k||0.018% $9.4m|
|Independent Director||22.4yrs||US$482.71k||0.011% $5.5m|
|Independent Director||24.8yrs||US$428.45k||0.0063% $3.3m|
|Independent Director||11.6yrs||US$452.45k||0.0034% $1.7m|
|Independent Director||12.1yrs||US$400.23k||0.0063% $3.3m|
|Independent Director||9.9yrs||US$407.95k||0.0086% $4.5m|
|Independent Director||10.7yrs||US$413.45k||0.0063% $3.3m|
|Independent Director||10.7yrs||US$407.95k||0.0063% $3.3m|
Experienced Board: BIIB's board of directors are seasoned and experienced ( 10.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biogen Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Biogen Inc.
- Ticker: BIIB
- Exchange: WBAG
- Founded: 1978
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$56.997b
- Listing Market Cap: US$51.930b
- Shares outstanding: 174.06m
- Website: https://www.biogen.com
Number of Employees
- Biogen Inc.
- 225 Binney Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIIB||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Sep 1991|
|IDP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 1991|
|IDP||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Sep 1991|
|BIIB||SNSE (Santiago Stock Exchange)||Yes||Common Stock||CL||USD||Sep 1991|
|BIIB *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Sep 1991|
|BIIB||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Sep 1991|
|BIIB-U||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Sep 1991|
|BIIB||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Sep 1991|
|BIIB34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 1/6 COM USD0.0005||BR||BRL||Apr 2016|
|BIIB||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 13 REP 1 COM USD0.0005||AR||ARS||Apr 2019|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases, and related therapeutic adjacencies in the United States, Europe, Asia, and internationally. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA, as well as ophthalmology biosimilar products, such as SB11 referencing LUCENTIS and SB15 referencing EYLEA. The company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. It also develops Opicinumab, BIIB091, and BIIB061 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB100, and BIIB110 for neuromuscular disorders; BIIB094 and BIIB054 to treat movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and other diseases; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, BIIB093, and Natalizumab to treat acute neurology; and BIIB074 and BIIB095 for pain. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/27 23:35|
|End of Day Share Price||2020/02/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.